Company intelligence / Profile preview

CBS4

Ownership: Private
Development stage: Other

Overview

CBS4 is a biotechnology company focused on developing novel small molecule therapies targeting the cystathionine beta-synthase (CBS) enzyme. The company's primary focus is on addressing metabolic disorders such as homocystinuria, as well as exploring the role of CBS in conditions like Down syndrome and ischemic stroke. By modulating CBS activity, CBS4 aims to restore metabolic balance and mitigate the toxic effects of elevated homocysteine levels. The company is currently in the pre-clinical stage, advancing its lead candidates through optimization and early safety studies.

Therapeutic areas: CardiovascularRare DiseasesMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on CBS4.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBS4.

Explore the full profile